Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

s occurring in more than 10 percent of patients include febrile neutropenia, mucosal inflammation and infections. The 30-day all-cause mortality rate was 17 percent, which compares favorably to standard induction chemotherapy. Infection was the most common cause of early mortality.

Pre-specified complete remission criteria were exceeded in Schedule A. In an effort to improve tolerability while maintaining anti-leukemic activity, an alternative dose regimen is being investigated. Twenty-one patients have been enrolled and treated with 72 mg/m(2) of voreloxin dosed weekly for two weeks (Schedule B). Early data from these patients suggest that Schedule B appears to be better tolerated and anti-leukemic activity has been maintained. To date, of 18 evaluable patients, one achieved a CRp and five are hypoplastic and are awaiting hematologic count recovery. Three additional patients with bone marrow blast reductions are undergoing second induction cycles of treatment. Patients on Schedule B have demonstrated improved tolerability. The 30-day all-cause mortality is currently 6 percent.

"We have made great strides this year in our voreloxin program," said Daniel Swisher, Chief Executive Officer of Sunesis. "In just over six months, more than 50 patients have been enrolled in the REVEAL-1 Phase 2 trial. We believe this underscores the enthusiasm of the clinical investigators for voreloxin and the high unmet medical need for elderly AML patients."

"Voreloxin's anti-leukemic activity in this previously untreated, older adult patient population with AML is promising," said Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, and an investigator in the study. "I am encouraged by the complete remissions observed thus far in patients who are unlikely to benefit from standard induction therapy."

'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group,s experts are ... the Affordable Care Act (ACA), which has ... therapies. The ACA altered how Managed Care ... and expanded access via government-supported programs. Dynamic ... marketplaces set up by states or the ...
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
(Date:7/31/2014)... Iowa , July 31, 2014 For ... California , Art,s-Way Scientific has earned ... With competition in over 30 categories, MBI,s ... for MBI members, which include building manufacturers, dealers, and ... is an excellent example the capability of our team," ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... serving the pharmaceutical, biotechnology, and medical device industries, ... today announced its financial results for third-quarter 2010. ... (Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO ) Third-Quarter ...
... LLC (US HIFU), a world leader in minimally invasive ... the Sonablate ® 500 (Sonablate) and Sonatherm ® ... 18 clinical trial sites involved in the recurrent prostate ... prostate cancer trial, or STAR trial, is a multi-center ...
Cached Medicine Technology:WuXi PharmaTech Announces Third-Quarter 2010 Results 2WuXi PharmaTech Announces Third-Quarter 2010 Results 3WuXi PharmaTech Announces Third-Quarter 2010 Results 4WuXi PharmaTech Announces Third-Quarter 2010 Results 5WuXi PharmaTech Announces Third-Quarter 2010 Results 6WuXi PharmaTech Announces Third-Quarter 2010 Results 7WuXi PharmaTech Announces Third-Quarter 2010 Results 8WuXi PharmaTech Announces Third-Quarter 2010 Results 9WuXi PharmaTech Announces Third-Quarter 2010 Results 10WuXi PharmaTech Announces Third-Quarter 2010 Results 11WuXi PharmaTech Announces Third-Quarter 2010 Results 12WuXi PharmaTech Announces Third-Quarter 2010 Results 13WuXi PharmaTech Announces Third-Quarter 2010 Results 14WuXi PharmaTech Announces Third-Quarter 2010 Results 15WuXi PharmaTech Announces Third-Quarter 2010 Results 16US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment 2US HIFU Announces That 18 Recurrent Prostate Cancer Clinical Trial Sites Are Open For Enrollment 3
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 United Theological ... its faculty, Anthony Le Donne and Peter J. Bellini. ... Also new to United is a Director of Non-Degree ... 1. , Anthony Le Donne, Assistant Professor of ... Kingdom. He teaches New Testament, Second Temple Judaism, and ...
(Date:7/31/2014)... 31, 2014 Ticket Down is ... Finals tickets at the Sun Life Stadium in Miami ... Cup is now underway. Residents and diehard soccer fans from ... watch the Guinness International Champions Cup final in person at ... in the tournament have been split into two groups where ...
(Date:7/31/2014)... 2014 Daily Gossip indicates in its ... for this health problem. However, this is not a ... was created by Peter Bansby, who decided to reveal ... all over the world find a unique way of ... to view pros and cons from a full Neuropathy ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2
... ... of their new ReActive™ Court Surface. , ... Salt Lake City, Utah (PRWEB) February 7, 2010 -- SnapSports today announced the ... new system is its adherence to metric standards, while still utilizing all of the patented ...
... support, researchers say , FRIDAY, Feb. 5 (HealthDay News) -- ... a new study suggests. , Researchers conducted PET scans of ... social status and social support. The results suggest that social ... dopamine D2/D3 receptors in an area of the brain called ...
... Amy ... her nursing career more than 30 years ago. Amy will assume the CEO post on March ... Washington, DC (Vocus) February ... Washington, D.C., where she began her nursing career more than 30 years ago. Amy will assume ...
... ... their newest “Select Partner”. As a MedicalSpaMD Select Partner, Shine Teeth Whitening gives ... $300M teeth whitening industry with no training and no equipment required. , ... Salt Lake City, UT (Vocus) ...
... ... Creams N, Lotions Facebook page or followers of their Twitter handle, @100sheabutter. Five randomly selected ... , ... 2010 -- Reforma Group is announcing a special Valentine,s Day giveaway to fans of their ...
... , , LAKE FOREST, Ill. ... Mutual Holding Company and Health Fitness Corporation (NYSE AMEX: ... has granted early termination of the waiting period under the ... of HealthFitness. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , On ...
Cached Medicine News:Health News:SnapSports Releases ReActive Court Surfacing For The International Sports Market 2Health News:Dopamine Levels in Brain May Determine Social Status 2Health News:Providence Hospital Selects Amy Freeman as President and CEO 2Health News:Providence Hospital Selects Amy Freeman as President and CEO 3Health News:MedicalSpaMD Announces Exciting New Partnership 2Health News:Romantic Valentine's Day Gift Ideas: Keep Your Skin Soft & Naughty Gift Basket Giveaway 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... to 12 L/min of Type I ultrapure ... The Super-Q Plus System is designed to ... has been pretreated by reverse osmosis, distillation ... ultrapure water quality which exceeds Type I ...
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
TOPLOAD 3200/0.01G, BL3200H. Touch-key external calibration only. Requires calibration weights (either 2000g or 3000g). 120/240V A/C adapter, Lock-down Ring, In-use Protective Cover....
Medicine Products: